 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...177178179180181182183184185186187...235236» |
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Study of the Combination of Apatinib and POF (clinicaltrials.gov) - Oct 15, 2018
P2, N=26, Not yet recruiting, Sponsor: Fujian Cancer Hospital
- | Trial completion date, Metastases: PRODIGE 35-PANOPTIMOX: First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem (clinicaltrials.gov) - Oct 15, 2018
P2, N=276, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Trial completion date: Jun 2019 --> Feb 2019
- | Trial completion date, Metastases: PRODIGE 37-FIRGEMAX: FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine (clinicaltrials.gov) - Oct 15, 2018
P2, N=127, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Trial completion date: Jun 2019 --> Feb 2019 Trial completion date: Dec 2020 --> Nov 2018
- | Bavencio (avelumab) / EMD Serono
Enrollment open, Trial initiation date, Tumor mutational burden, PD(L)-1 Biomarker: SAMCO: Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (clinicaltrials.gov) - Oct 15, 2018
P2, N=118, Recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Trial completion date: Dec 2020 --> Nov 2018 Not yet recruiting --> Recruiting | Initiation date: Sep 2017 --> Apr 2018
- ||||| BI 695502 (bevacizumab biosimilar) / Boehringer Ingelheim
Trial completion, Metastases: INVICTAN (clinicaltrials.gov) - Oct 12, 2018
P3, N=123, Completed, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting | Initiation date: Sep 2017 --> Apr 2018 Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Trial initiation date, Metastases: Conversion From Unresectable To Resectable Metastatic Colorectal Cancer. (clinicaltrials.gov) - Oct 12, 2018
P2, N=32, Not yet recruiting, Sponsor: University of Saskatchewan
Active, not recruiting --> Completed Initiation date: Sep 2018 --> Jun 2019
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment open, Metastases: LOGIC: FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma (clinicaltrials.gov) - Oct 12, 2018
P2, N=36, Recruiting, Sponsor: University of Saskatchewan
Initiation date: Sep 2018 --> Jun 2019 Not yet recruiting --> Recruiting
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P1 trial: Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Oct 10, 2018
P1, N=30, Recruiting, Sponsor: Benaroya Research Institute
- | Avastin (bevacizumab) / Roche
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer (clinicaltrials.gov) - Oct 10, 2018
P1, N=52, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial completion date: Sep 2022 --> Dec 2021 | Initiation date: Sep 2018 --> Dec 2018 | Trial primary completion date: Sep 2021 --> Dec 2021
- | Opdivo (nivolumab) / BMS
Enrollment open: RELATIVITY-060: An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers (clinicaltrials.gov) - Oct 10, 2018
P2, N=250, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Sep 2022 --> Dec 2021 | Initiation date: Sep 2018 --> Dec 2018 | Trial primary completion date: Sep 2021 --> Dec 2021 Not yet recruiting --> Recruiting
- | alisertib (MLN8237) / Puma
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors (clinicaltrials.gov) - Oct 9, 2018
P1, N=14, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=30 --> 14 | Trial primary completion date: Jun 2017 --> Sep 2018
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
New P2 trial, Combination therapy, Metastases: CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Oct 9, 2018
P2, N=33, Not yet recruiting, Sponsor: Jeffrey Hardacre
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg., gemcitabine / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: NEOPAN: A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma (clinicaltrials.gov) - Oct 5, 2018
P3, N=170, Recruiting, Sponsor: UNICANCER
Active, not recruiting --> Completed | N=30 --> 14 | Trial primary completion date: Jun 2017 --> Sep 2018 Trial completion date: Mar 2020 --> Mar 2022 | Trial primary completion date: Mar 2019 --> Mar 2021
- | Trial completion date, Trial primary completion date, Metastases: QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine (clinicaltrials.gov) - Oct 5, 2018
P1/2, N=382, Recruiting, Sponsor: NantKwest, Inc.
Trial completion date: Mar 2020 --> Mar 2022 | Trial primary completion date: Mar 2019 --> Mar 2021 Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2019 --> Jul 2020
- | Stivarga (regorafenib) / Bayer
New trial, Metastases: Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI (clinicaltrials.gov) - Oct 4, 2018
P=N/A, N=41, Completed, Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
- || 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Trial completion date, Trial primary completion date: Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Oct 4, 2018
P2, N=111, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2019 --> Jul 2020 Trial completion date: Oct 2018 --> Oct 2019 | Trial primary completion date: Oct 2018 --> Oct 2019
- | bortezomib / Generic mfg., thioguanine / Generic mfg.
Trial primary completion date: AALL1231: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Oct 4, 2018
P3, N=1400, Suspended, Sponsor: National Cancer Institute (NCI)
Trial completion date: Oct 2018 --> Oct 2019 | Trial primary completion date: Oct 2018 --> Oct 2019 Trial primary completion date: Feb 2022 --> Dec 2023
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment open, Trial initiation date, Metastases: NIFTY: Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Oct 3, 2018
P2, N=174, Recruiting, Sponsor: Changhoon Yoo
Trial primary completion date: Feb 2022 --> Dec 2023 Not yet recruiting --> Recruiting | Initiation date: Jun 2018 --> Sep 2018
- | bemarituzumab (AMG 552) / Amgen
New P3 trial, Metastases: FIGHT: A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (clinicaltrials.gov) - Oct 2, 2018
P3, N=548, Recruiting, Sponsor: Five Prime Therapeutics, Inc.
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer (clinicaltrials.gov) - Oct 2, 2018
P=N/A, N=20, Recruiting, Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Not yet recruiting --> Recruiting | Initiation date: Jun 2018 --> Sep 2018 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Sep 2018 --> Sep 2019
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Enrollment closed: SULTAN: Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network (clinicaltrials.gov) - Oct 2, 2018
P2, N=140, Active, not recruiting, Sponsor: UNICANCER
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Sep 2018 --> Sep 2019 Not yet recruiting --> Active, not recruiting
- | Enrollment open: Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Oct 2, 2018
P1, N=20, Recruiting, Sponsor: University of Louisville
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | CYAD-101 / Celyad Oncology
New P1 trial, CAR T-Cell Therapy, Metastases: alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells (clinicaltrials.gov) - Oct 2, 2018
P1, N=36, Not yet recruiting, Sponsor: Celyad (formerly named Cardio3 BioSciences)
- | Stivarga (regorafenib) / Bayer
Trial completion date, Trial termination: Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX (clinicaltrials.gov) - Oct 1, 2018
P2, N=24, Terminated, Sponsor: US Oncology Research
Not yet recruiting --> Recruiting Trial completion date: Sep 2019 --> Sep 2017 | Active, not recruiting --> Terminated; insufficient accrual
- | New P3 trial, Head-to-Head, Metastases: PELICAN: Pancreatic Locally Advanced Irresectable Cancer Ablation (clinicaltrials.gov) - Sep 30, 2018
P3, N=228, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- | spartalizumab (PDR001) / Novartis
Trial completion, Combination therapy, Metastases: PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer (clinicaltrials.gov) - Sep 28, 2018
P1, N=1, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: Sep 2019 --> Sep 2017 | Active, not recruiting --> Terminated; insufficient accrual Terminated --> Completed
- | Rituxan (rituximab) / Roche
New P1 trial: LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma (clinicaltrials.gov) - Sep 26, 2018
P1, N=6, Not yet recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- | Trial completion date, Trial primary completion date, Monotherapy, Metastases: Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) (clinicaltrials.gov) - Sep 24, 2018
P1, N=408, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Terminated --> Completed Trial completion date: Mar 2021 --> Jul 2021 | Trial primary completion date: Mar 2021 --> Jul 2021
- | irinotecan / Generic mfg.
Enrollment open: Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma (clinicaltrials.gov) - Sep 20, 2018
P2, N=25, Recruiting, Sponsor: Khon Kaen University
Trial completion date: Mar 2021 --> Jul 2021 | Trial primary completion date: Mar 2021 --> Jul 2021 Not yet recruiting --> Recruiting
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg.
Clinical, P2 data, Clinical Trial,Phase II, Journal: Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial. (Pubmed Central) - Sep 19, 2018
Neoadjuvant consolidation chemotherapy may have benefits beyond increasing pathological complete response rates. See Video Abstract at http://links.lww.com/DCR/A739.
- | Enrollment open: Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation (clinicaltrials.gov) - Sep 19, 2018
P3, N=776, Recruiting, Sponsor: Sun Yat-sen University
See Video Abstract at http://links.lww.com/DCR/A739. Not yet recruiting --> Recruiting
- | New P3 trial: FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM (clinicaltrials.gov) - Sep 18, 2018
P3, N=160, Not yet recruiting, Sponsor: Sun Yat-sen University
- | NN1213 / Novo Nordisk
Enrollment closed: SINTART2: Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients (clinicaltrials.gov) - Sep 18, 2018
P2, N=27, Active, not recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | NN1213 / Novo Nordisk
Enrollment closed, Surgery: SINTART 1: Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients (clinicaltrials.gov) - Sep 18, 2018
P2, N=41, Active, not recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | napabucasin (BBI608) / Sumitomo Pharma
Enrollment change, Trial primary completion date, Combination therapy, Metastases: A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer (clinicaltrials.gov) - Sep 18, 2018
P1, N=139, Active, not recruiting, Sponsor: Boston Biomedical, Inc
Recruiting --> Active, not recruiting N=250 --> 139 | Trial primary completion date: Dec 2018 --> Mar 2019
- | Tecentriq (atezolizumab) / Roche
Enrollment open, Combination therapy: DANTE: Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness (clinicaltrials.gov) - Sep 18, 2018
P2, N=295, Recruiting, Sponsor: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
N=250 --> 139 | Trial primary completion date: Dec 2018 --> Mar 2019 Not yet recruiting --> Recruiting
- | Opdivo (nivolumab) / BMS
Enrollment open: Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer (clinicaltrials.gov) - Sep 17, 2018
P2, N=170, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || namilumab (IZN-101) / Amgen, Izana Biosci, Roivant
Trial primary completion date, Combination therapy: NEXUS: Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Sep 14, 2018
P2, N=108, Completed, Sponsor: Takeda
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2016 --> May 2016
- | varlitinib (ASLAN001) / ASLAN Pharma
Enrollment change, Combination therapy: ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin (clinicaltrials.gov) - Sep 14, 2018
P1, N=60, Recruiting, Sponsor: National Cancer Centre, Singapore
Trial primary completion date: Nov 2016 --> May 2016 N=18 --> 60
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment open, Combination therapy: NEO-Nal- IRI: A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma (clinicaltrials.gov) - Sep 14, 2018
P2, N=28, Recruiting, Sponsor: University of Florida
N=18 --> 60 Not yet recruiting --> Recruiting
- | New P3 trial: Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation (clinicaltrials.gov) - Sep 14, 2018
P3, N=776, Not yet recruiting, Sponsor: Sun Yat-sen University
- | Ukoniq (umbralisib) / TG Therap
Trial primary completion date, Combination therapy: TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Sep 13, 2018
P1, N=65, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2018 --> Dec 2018
- | Reolysin (pelareorep) / Oncolytics, Andrus Reo
Trial completion, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, Metastases: Study of Pembrolizumab With REOLYSIN (clinicaltrials.gov) - Sep 13, 2018
P1b, N=11, Completed, Sponsor: Oncolytics Biotech
Trial primary completion date: Jun 2018 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Aug 2018 | Trial primary completion date: Oct 2018 --> Mar 2018
- | vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
New P1 trial, Combination therapy, Metastases: MP-PDAC-01: Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel (clinicaltrials.gov) - Sep 12, 2018
P1b, N=36, Not yet recruiting, Sponsor: Samsung Medical Center
- | Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: FABLOx: Study of 5-fluorouracil (5-FU), Nab (clinicaltrials.gov) - Sep 11, 2018
P1/2, N=12, Active, not recruiting, Sponsor: Celgene
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Aug 2018 | Trial primary completion date: Oct 2018 --> Mar 2018 Trial completion date: May 2020 --> Oct 2018 | Trial primary completion date: May 2020 --> Oct 2018
- | Trial completion date, Trial termination, Trial primary completion date, Metastases: FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas (clinicaltrials.gov) - Sep 11, 2018
P2, N=2, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: May 2020 --> Oct 2018 | Trial primary completion date: May 2020 --> Oct 2018 Trial completion date: Mar 2020 --> Jul 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2019 --> Jan 2018; Slow accrual
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial initiation date, Metastases: Avenger 500: Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Sep 11, 2018
P3, N=500, Not yet recruiting, Sponsor: Rafael Pharmaceuticals Inc.
Trial completion date: Mar 2020 --> Jul 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2019 --> Jan 2018; Slow accrual Initiation date: Jul 2018 --> Oct 2018
- | Graspa (eryaspase) / PHAXIAM Therap
New P3 trial, Combination therapy: Trybeca-1: Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC (clinicaltrials.gov) - Sep 11, 2018
P3, N=482, Not yet recruiting, Sponsor: ERYtech Pharma
- | BMS-813160 / BMS, Opdivo (nivolumab) / BMS
Enrollment change, Trial completion date: A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Sep 10, 2018
P1b/2, N=348, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Jul 2018 --> Oct 2018 N=260 --> 348 | Trial completion date: Mar 2021 --> Dec 2021
- | oxaliplatin / Generic mfg.
Retrospective data, Journal: Protective effect of Korean red ginseng on oxaliplatin-mediated splenomegaly in colon cancer. (Pubmed Central) - Sep 7, 2018
This study investigated how adding Korean red ginseng extract (KRG) to folinic acid, fluorouracil and oxaliplatin (FOLFOX) chemotherapy affected the rate of splenomegaly in colon cancer...Adding KRG during FOLFOX chemotherapy for colon cancer might protect against oxaliplatin-induced splenomegaly. The protective effect of Korean red ginseng should be investigated with further research.